PE20030238A1 - Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales - Google Patents
Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronalesInfo
- Publication number
- PE20030238A1 PE20030238A1 PE2002000610A PE2002000610A PE20030238A1 PE 20030238 A1 PE20030238 A1 PE 20030238A1 PE 2002000610 A PE2002000610 A PE 2002000610A PE 2002000610 A PE2002000610 A PE 2002000610A PE 20030238 A1 PE20030238 A1 PE 20030238A1
- Authority
- PE
- Peru
- Prior art keywords
- spinal
- brain
- treatment
- trifluoromethyl
- benzyl
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- JKHCSKNIYWXLNC-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1N=CC=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JKHCSKNIYWXLNC-UHFFFAOYSA-N 0.000 abstract 1
- GTBUTLFXQOBLCG-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-4-(2-methylphenyl)pyridine-3-carboxamide Chemical compound C=1N=CC=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GTBUTLFXQOBLCG-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE AL USO DE ANTAGONISTA DEL RECEPTOR NK-1 DE FORMULA I DONDE R ES H, ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO; R1 ES H, HALOGENO; R Y R1 SON -CH=CH-CH=CH-; R2 Y R2' SON H, HALO, TRIFLUOROMETILO, ALQUILO, ALCOXILO, ENTRE OTROS; R2 Y R2' JUNTOS -CH=CH-CH=-CH- SUSTITUIDOS CON ALQUILO, HALO, ALCOXI; R3 ES H, ALQUILO, ENTRE OTROS; R4 ES H, -N(R5)2, -N(R5)(CH2)nOH, ENTRE OTROS; R5 ES H, CICLOALQUILO C3-C6, BENCILO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-o-TOLIL-NICOTINAMIDA, N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-(2-CLORO-FENIL)-NICOTINAMIDA, N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-(2-TRIFLUOROFENIL)-NICOTINAMIDA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR NK-1 Y SON UTILES PARA EL TRATAMIENTO DE LESIONES CEREBRALES, ESPINALES, NEURONALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01116812 | 2001-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030238A1 true PE20030238A1 (es) | 2003-03-19 |
Family
ID=8178001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000610A PE20030238A1 (es) | 2001-07-10 | 2002-07-08 | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20030083345A1 (es) |
| EP (2) | EP1621195A3 (es) |
| JP (1) | JP2004536119A (es) |
| KR (1) | KR100589106B1 (es) |
| CN (1) | CN100346789C (es) |
| AR (1) | AR037008A1 (es) |
| AU (1) | AU2002328837B2 (es) |
| BR (1) | BR0210893A (es) |
| CA (1) | CA2451566C (es) |
| GT (1) | GT200200143A (es) |
| HR (1) | HRP20031071A2 (es) |
| HU (1) | HUP0401210A3 (es) |
| IL (1) | IL159350A0 (es) |
| MX (1) | MXPA04000278A (es) |
| NO (1) | NO332847B1 (es) |
| NZ (1) | NZ530107A (es) |
| PA (1) | PA8549901A1 (es) |
| PE (1) | PE20030238A1 (es) |
| PL (1) | PL211246B1 (es) |
| RU (1) | RU2304435C2 (es) |
| UY (1) | UY27374A1 (es) |
| WO (1) | WO2003006016A2 (es) |
| ZA (1) | ZA200400138B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| CA2530886C (en) * | 2003-07-03 | 2013-05-28 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
| GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
| ATE500224T1 (de) | 2004-07-06 | 2011-03-15 | Hoffmann La Roche | Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| CA2601935C (en) * | 2005-02-22 | 2013-04-09 | F. Hoffmann-La Roche Ag | Nk1 antagonists |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| AU2006226665B2 (en) * | 2005-03-23 | 2011-01-27 | Helsinn Healthcare S.A. | Metabolites for NK-I antagonists for emesis |
| NZ567892A (en) | 2005-11-08 | 2010-12-24 | Vertex Pharma | Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2010000724A (es) * | 2007-07-19 | 2010-06-02 | Adelaide Res & Innovation Pty | Metodo para reducir presion intracraneal. |
| PL2225230T3 (pl) | 2007-12-07 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego |
| DK2639224T3 (en) | 2007-12-07 | 2016-10-17 | Vertex Pharma | A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| US20160129007A1 (en) * | 2013-07-02 | 2016-05-12 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV |
| BR112015032161A2 (pt) * | 2013-07-02 | 2017-07-25 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p |
| HK1221637A1 (zh) * | 2013-07-02 | 2017-06-09 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 用於预防和/或治疗ii型慢性创伤性脑病的方法 |
| CA2930008A1 (en) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
| PL3068392T3 (pl) | 2013-11-12 | 2021-07-19 | Vertex Pharmaceuticals Incorporated | Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| CN107110831B (zh) | 2014-11-18 | 2020-02-21 | 弗特克斯药品有限公司 | 进行高通量试验高效液相色谱的方法 |
| CN111741755B (zh) * | 2018-02-02 | 2024-04-16 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 肠胃外制剂及其用途 |
| KR101970099B1 (ko) * | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | 척수 손상의 예방 및 치료용 조성물 |
| KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
| CN114466683A (zh) * | 2019-08-23 | 2022-05-10 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 治疗方法及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
| CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5607947A (en) * | 1995-02-21 | 1997-03-04 | Eli Lilly And Company | Pyrrolidinyl tachykinin receptor antagonists |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| JP2002506459A (ja) * | 1997-06-27 | 2002-02-26 | メルク シヤープ エンド ドーム リミテツド | 置換された３−（ベンジルアミノ）ピペリジン誘導体およびその治療薬としての使用 |
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| HUP0200139A3 (en) * | 1999-02-24 | 2003-01-28 | Hoffmann La Roche | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists, process for their preparation and pharmaceutical compositions containing them |
| ATE277905T1 (de) * | 1999-02-24 | 2004-10-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| PT1103545E (pt) * | 1999-11-29 | 2004-03-31 | Hoffmann La Roche | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida |
| US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
-
2002
- 2002-07-02 US US10/187,587 patent/US20030083345A1/en not_active Abandoned
- 2002-07-03 CN CNB028135423A patent/CN100346789C/zh not_active Expired - Lifetime
- 2002-07-03 HR HR20031071A patent/HRP20031071A2/xx not_active Application Discontinuation
- 2002-07-03 EP EP05017203A patent/EP1621195A3/en not_active Withdrawn
- 2002-07-03 JP JP2003511822A patent/JP2004536119A/ja active Pending
- 2002-07-03 CA CA2451566A patent/CA2451566C/en not_active Expired - Lifetime
- 2002-07-03 IL IL15935002A patent/IL159350A0/xx unknown
- 2002-07-03 KR KR1020047000395A patent/KR100589106B1/ko not_active Expired - Lifetime
- 2002-07-03 EP EP02764617A patent/EP1406618A2/en not_active Withdrawn
- 2002-07-03 WO PCT/EP2002/007323 patent/WO2003006016A2/en not_active Ceased
- 2002-07-03 PL PL369535A patent/PL211246B1/pl unknown
- 2002-07-03 AU AU2002328837A patent/AU2002328837B2/en not_active Expired
- 2002-07-03 RU RU2004102397/15A patent/RU2304435C2/ru active
- 2002-07-03 BR BR0210893-3A patent/BR0210893A/pt not_active IP Right Cessation
- 2002-07-03 NZ NZ530107A patent/NZ530107A/en unknown
- 2002-07-03 MX MXPA04000278A patent/MXPA04000278A/es active IP Right Grant
- 2002-07-03 HU HU0401210A patent/HUP0401210A3/hu unknown
- 2002-07-05 PA PA20028549901A patent/PA8549901A1/es unknown
- 2002-07-08 PE PE2002000610A patent/PE20030238A1/es not_active Application Discontinuation
- 2002-07-08 AR ARP020102546A patent/AR037008A1/es unknown
- 2002-07-09 GT GT200200143A patent/GT200200143A/es unknown
- 2002-07-09 UY UY27374A patent/UY27374A1/es not_active Application Discontinuation
-
2004
- 2004-01-07 NO NO20040057A patent/NO332847B1/no not_active IP Right Cessation
- 2004-01-08 ZA ZA2004/00138A patent/ZA200400138B/en unknown
-
2006
- 2006-07-05 US US11/481,216 patent/US20060247240A1/en not_active Abandoned
-
2010
- 2010-09-21 US US12/886,691 patent/US20110053954A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| PE20010009A1 (es) | Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1 | |
| SE0104332D0 (sv) | Therapeutic agents | |
| PE20000170A1 (es) | Derivados benzosulfonas | |
| PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| AR021055A1 (es) | Derivados de pirazolopiridina | |
| PE20021094A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos | |
| PE20050598A1 (es) | Compuestos moduladores de cb1 | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20041061A1 (es) | Imidazol-4-il-etinil-piridina | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| TR200401546T4 (tr) | Piperazin türevleri, hazırlanmaları ve merkezi sinir sistemi (CNS) bozukluklarının tedavisinde kullanımları | |
| ES2113081T3 (es) | 1,4-benzotiazepinas utiles como agentes neurologicos. | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| NZ528997A (en) | Sulfonamides | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| EA200001114A3 (ru) | 2-(3,5-БИСТРИФТОРОМЕТИЛФЕНИЛ)-N-МЕТИЛ-N-(6-МОРФОЛИН-4-ИЛ-4-о-ТОЛИЛПИРИДИН-3-ИЛ)ИЗОБУТИРАМИД | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| YU64901A (sh) | Derivati bifenila | |
| PE20040172A1 (es) | Imidazolinilmetil aralquilsulfonamidas | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| EA200001184A1 (ru) | Фенилсульфонамидфенилэтиламины, полезные в качестве допаминовых рецепторов | |
| TR200400027T4 (tr) | 5HT7 Alıcı Agonist Aktivitesine Sahip 4-(2-Piridil Piperazinler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |